questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Globulines
Sérum-globulines
Immunoglobulines
Anticorps
Autoanticorps
Autoanticorps : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Autoanticorps
Tests de laboratoire
Anticorps antinucléaires
Autoanticorps
Maladies auto-immunes
Autoanticorps
Autoanticorps
Asymptomatique
Symptômes
5
Douleurs articulaires
Polyarthrite rhumatoïde
Troubles neurologiques
Sclérose en plaques
Éruptions cutanées
Lupus érythémateux
Organes internes
Maladies auto-immunes
Prévention
5
Prévention
Mode de vie sain
Vaccinations
Autoanticorps
Stress
Maladies auto-immunes
Alimentation
Inflammation
Examens médicaux
Prévention
Traitements
5
Immunosuppresseurs
Corticostéroïdes
Traitement
Maladies auto-immunes
Thérapies biologiques
Autoanticorps
Mode de vie
Gestion des symptômes
Complications
5
Complications
Dommages aux organes
Maladies cardiovasculaires
Autoanticorps
Complications
Gestion des symptômes
Infections
Maladies auto-immunes
Complications neurologiques
Troubles cognitifs
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Facteurs environnementaux
Infections
Tabagisme
Maladies auto-immunes
Déséquilibres hormonaux
Autoanticorps
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Autoanticorps : Questions médicales les plus fréquentes",
"headline": "Autoanticorps : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Autoanticorps : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-22",
"dateModified": "2025-02-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Autoanticorps"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Anticorps",
"url": "https://questionsmedicales.fr/mesh/D000906",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps",
"code": {
"@type": "MedicalCode",
"code": "D000906",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-protéines citrullinées",
"alternateName": "Anti-Citrullinated Protein Antibodies",
"url": "https://questionsmedicales.fr/mesh/D000075422",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-protéines citrullinées",
"code": {
"@type": "MedicalCode",
"code": "D000075422",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.095"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antinucléaires",
"alternateName": "Antibodies, Antinuclear",
"url": "https://questionsmedicales.fr/mesh/D000974",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antinucléaires",
"code": {
"@type": "MedicalCode",
"code": "D000974",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.204"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antiphospholipides",
"alternateName": "Antibodies, Antiphospholipid",
"url": "https://questionsmedicales.fr/mesh/D017152",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiphospholipides",
"code": {
"@type": "MedicalCode",
"code": "D017152",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.210"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anticardiolipines",
"alternateName": "Antibodies, Anticardiolipin",
"url": "https://questionsmedicales.fr/mesh/D017153",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anticardiolipines",
"code": {
"@type": "MedicalCode",
"code": "D017153",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.210.100"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Facteur néphritique C3",
"alternateName": "Complement C3 Nephritic Factor",
"url": "https://questionsmedicales.fr/mesh/D003178",
"about": {
"@type": "MedicalCondition",
"name": "Facteur néphritique C3",
"code": {
"@type": "MedicalCode",
"code": "D003178",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoconglutinines",
"alternateName": "Immunoconglutinins",
"url": "https://questionsmedicales.fr/mesh/D037561",
"about": {
"@type": "MedicalCondition",
"name": "Immunoconglutinines",
"code": {
"@type": "MedicalCode",
"code": "D037561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.390"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobulines thyréostimulantes",
"alternateName": "Immunoglobulins, Thyroid-Stimulating",
"url": "https://questionsmedicales.fr/mesh/D018828",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobulines thyréostimulantes",
"code": {
"@type": "MedicalCode",
"code": "D018828",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.480"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur rhumatoïde",
"alternateName": "Rheumatoid Factor",
"url": "https://questionsmedicales.fr/mesh/D012217",
"about": {
"@type": "MedicalCondition",
"name": "Facteur rhumatoïde",
"code": {
"@type": "MedicalCode",
"code": "D012217",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.732"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Autoanticorps",
"alternateName": "Autoantibodies",
"code": {
"@type": "MedicalCode",
"code": "D001323",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Iago Pinal-Fernandez",
"url": "https://questionsmedicales.fr/author/Iago%20Pinal-Fernandez",
"affiliation": {
"@type": "Organization",
"name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov."
}
},
{
"@type": "Person",
"name": "Katherine Pak",
"url": "https://questionsmedicales.fr/author/Katherine%20Pak",
"affiliation": {
"@type": "Organization",
"name": "Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA."
}
},
{
"@type": "Person",
"name": "Sarah L Tansley",
"url": "https://questionsmedicales.fr/author/Sarah%20L%20Tansley",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy and pharmacology, University of Bath, Bath, UK."
}
},
{
"@type": "Person",
"name": "Gunnar Houen",
"url": "https://questionsmedicales.fr/author/Gunnar%20Houen",
"affiliation": {
"@type": "Organization",
"name": "Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark. gh@ssi.dk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Polymyositis and dermatomyositis biomarkers.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37329941",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cca.2023.117443"
}
},
{
"@type": "ScholarlyArticle",
"name": "The rise and fall of troponin in a patient with polymyositis.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37336623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-255312"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pregnancy in adult-onset dermatomyositis/polymyositis: A systematic review.",
"datePublished": "2022-08-23",
"url": "https://questionsmedicales.fr/article/35867856",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/aji.13603"
}
},
{
"@type": "ScholarlyArticle",
"name": "Polymyositis/dermatomyositis readmissions: analysis of the nationwide readmission database.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37407906",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10067-023-06690-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Physical exercise for dermatomyositis and polymyositis: a systematic review and meta-analysis.",
"datePublished": "2022-07-12",
"url": "https://questionsmedicales.fr/article/35821167",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10067-022-06281-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Anticorps",
"item": "https://questionsmedicales.fr/mesh/D000906"
},
{
"@type": "ListItem",
"position": 8,
"name": "Autoanticorps",
"item": "https://questionsmedicales.fr/mesh/D001323"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Autoanticorps - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Autoanticorps",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Autoanticorps",
"description": "Comment détecte-t-on les autoanticorps ?\nQuels tests sont utilisés pour les autoanticorps ?\nLes autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?\nPeut-on avoir des autoanticorps sans symptômes ?\nQuel rôle jouent les autoanticorps dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Polymyositis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Autoanticorps",
"description": "Quels symptômes sont associés aux autoanticorps ?\nLes autoanticorps causent-ils des douleurs articulaires ?\nPeut-on avoir des symptômes neurologiques avec des autoanticorps ?\nLes éruptions cutanées sont-elles liées aux autoanticorps ?\nLes autoanticorps peuvent-ils affecter les organes internes ?",
"url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Polymyositis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Autoanticorps",
"description": "Peut-on prévenir la production d'autoanticorps ?\nLes vaccinations influencent-elles les autoanticorps ?\nLe stress peut-il augmenter les autoanticorps ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes examens médicaux réguliers aident-ils à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Polymyositis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Autoanticorps",
"description": "Comment traite-t-on les maladies liées aux autoanticorps ?\nLes traitements sont-ils les mêmes pour tous les autoanticorps ?\nLes thérapies biologiques sont-elles efficaces contre les autoanticorps ?\nPeut-on guérir des maladies causées par des autoanticorps ?\nLes changements de mode de vie aident-ils à gérer les autoanticorps ?",
"url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Polymyositis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Autoanticorps",
"description": "Quelles complications peuvent survenir avec des autoanticorps ?\nLes autoanticorps peuvent-ils causer des maladies cardiovasculaires ?\nLes complications sont-elles réversibles ?\nLes infections sont-elles plus fréquentes avec des autoanticorps ?\nLes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Polymyositis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Autoanticorps",
"description": "Quels sont les facteurs de risque pour les autoanticorps ?\nL'âge influence-t-il la production d'autoanticorps ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLe tabagisme est-il un facteur de risque ?\nLes déséquilibres hormonaux affectent-ils les autoanticorps ?",
"url": "https://questionsmedicales.fr/mesh/D001323?mesh_terms=Polymyositis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on les autoanticorps ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les autoanticorps sont détectés par des tests sanguins spécifiques, comme l'ELISA."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les autoanticorps ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests courants incluent le dosage des anticorps antinucléaires (ANA) et des anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Les autoanticorps sont-ils toujours présents dans les maladies auto-immunes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur présence peut varier selon la maladie et le stade de la maladie."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des autoanticorps sans symptômes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent avoir des autoanticorps sans présenter de symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les autoanticorps dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à confirmer le diagnostic de maladies auto-immunes et à évaluer leur activité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux autoanticorps ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais peuvent inclure fatigue, douleurs articulaires et éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les autoanticorps causent-ils des douleurs articulaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent provoquer des douleurs articulaires dans des maladies comme la polyarthrite rhumatoïde."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques avec des autoanticorps ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains autoanticorps sont associés à des troubles neurologiques comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Les éruptions cutanées sont-elles liées aux autoanticorps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir dans des maladies comme le lupus érythémateux systémique."
}
},
{
"@type": "Question",
"name": "Les autoanticorps peuvent-ils affecter les organes internes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent endommager des organes comme les reins, le cœur ou les poumons dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la production d'autoanticorps ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode garantie, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations influencent-elles les autoanticorps ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent déclencher des autoanticorps, mais les bénéfices l'emportent souvent."
}
},
{
"@type": "Question",
"name": "Le stress peut-il augmenter les autoanticorps ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber les maladies auto-immunes et augmenter les autoanticorps."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants et en oméga-3 peut aider à réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Les examens médicaux réguliers aident-ils à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on les maladies liées aux autoanticorps ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des immunosuppresseurs, des anti-inflammatoires et des corticostéroïdes."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils les mêmes pour tous les autoanticorps ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le traitement dépend du type de maladie auto-immune et des autoanticorps présents."
}
},
{
"@type": "Question",
"name": "Les thérapies biologiques sont-elles efficaces contre les autoanticorps ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines thérapies biologiques ciblent spécifiquement les mécanismes des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Peut-on guérir des maladies causées par des autoanticorps ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de guérison, mais les traitements peuvent contrôler les symptômes et la progression."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils à gérer les autoanticorps ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée, l'exercice et la gestion du stress peuvent aider à la gestion."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des autoanticorps ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des dommages aux organes, des infections et des troubles auto-immuns."
}
},
{
"@type": "Question",
"name": "Les autoanticorps peuvent-ils causer des maladies cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains autoanticorps sont associés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent causer des dommages permanents."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles plus fréquentes avec des autoanticorps ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients avec des maladies auto-immunes ont un risque accru d'infections."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, comme des troubles cognitifs ou des crises."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les autoanticorps ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, le sexe féminin et certaines infections."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la production d'autoanticorps ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la production d'autoanticorps augmente souvent avec l'âge, surtout chez les femmes."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines ou à des infections peut déclencher la production d'autoanticorps."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à un risque accru de maladies auto-immunes et d'autoanticorps."
}
},
{
"@type": "Question",
"name": "Les déséquilibres hormonaux affectent-ils les autoanticorps ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les déséquilibres hormonaux, notamment chez les femmes, peuvent influencer la production d'autoanticorps."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 16/02/2025
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
4 publications dans cette catégorie
Affiliations :
Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Publications dans "Autoanticorps" :
4 publications dans cette catégorie
Affiliations :
Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Publications dans "Autoanticorps" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacy and pharmacology, University of Bath, Bath, UK.
Publications dans "Autoanticorps" :
3 publications dans cette catégorie
Affiliations :
Department of Autoimmunology, Statens Serum Institut, Copenhagen, Denmark. gh@ssi.dk.
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark. gh@ssi.dk.
Publications dans "Autoanticorps" :
3 publications dans cette catégorie
Affiliations :
Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Publications dans "Autoanticorps" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Publications dans "Autoanticorps" :
3 publications dans cette catégorie
Affiliations :
Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Department of Dermatology, International University of Health and Welfare Narita Hospital, Chiba 286-8520, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo 100-0013, Japan.
ProteoBridge Corporation, Tokyo 135-0064, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
ProteoBridge Corporation, Tokyo 135-0064, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
ProteoBridge Corporation, Tokyo 135-0064, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo 100-0013, Japan.
ProteoBridge Corporation, Tokyo 135-0064, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan.
Publications dans "Autoanticorps" :
Polymyositis (PM) and dermatomyositis (DM) are the two subtypes of idiopathic inflammatory myositis and are characterized as symmetrical progressive muscle weakness in the proximal extremities. PM/DM ...
Troponins are an excellent sensitive marker for myocardial ischaemic damage. However, there are several non-ischaemic cardiac and non-cardiac reasons for troponin elevation. Many cases of troponin T e...
Idiopathic inflammatory myopathy (IIM) in pregnancy is uncommon but may result in complications for both mother and the fetus....
In this systematic review, we summarized the current literature investigating outcomes of pregnancy related to the dermatomyositis/polymyositis (DM/PM) process....
We searched PubMed, Embase, Cochrane Library, and Web of Science databases and included 61 studies reporting the disease course, pregnancy outcomes, and management of both pregnancy and DM/PM in the f...
The present results underline the importance of good control of myopathy in optimizing the pregnancy outcomes of women with DM/PM....
There is a scarcity of national population-based studies on polymyositis (PM)/dermatomyositis (DM) readmissions in the USA. In this study, we aim to describe the rates, reasons for readmissions, and c...
We analyzed the 2018 Nationwide Readmissions Database (NRD). We included index hospitalizations for all adult DM/PM patients with a principal diagnosis of PM/DM using ICD-10 codes. We excluded electiv...
A total of 1610, 1286, and 842 index hospitalizations with a principal diagnosis of PM/DM, that were discharged alive, were included in the 30-, 90-, and 180-day readmission analysis, respectively. Am...
About a third of PM/DM hospitalized patients are readmitted within 180 days. Readmissions constitute a significant economic burden to the health care system. PM and sepsis are the main reasons for rea...
Trials regarding physical exercise in dermatomyositis (DM) and polymyositis (PM) are heterogeneous. We aimed to summarize and critically analyze the available evidence to support the hypothesis that e...
Observational studies have revealed a higher probability of hypothyroidism in patients with dermatomyositis (DM) or polymyositis (PM), but there is no consensus on whether hypothyroidism causally infl...
The genome-wide association data of hypothyroidism and dermatomyositis/polymyositis were obtained from the IEU Open GWAS project. Then, TSMR was used to determine whether hypothyroidism is causally as...
Sixty-eight SNPs for DM and 68 SNPs for PM were selected as the IVs (P<5×10...
In conclusion, the MR analysis results provided strong evidence to indicate that hypothyroidism might be causally associated with DM and PM. These findings may have important implications for the path...
Polymyositis (PM) and dermatomyositis (DM) are heterogeneous disorders. However, the etiology of PM/DM development has not been thoroughly clarified....
Gene expression data of PM/DM were obtained from Gene Expression Omnibus. We used robust rank aggregation (RRA) to identify differentially expressed genes (DEGs). Gene Ontology functional enrichment a...
Five datasets were included. The RRA integrated analysis identified 82 significant DEGs. Functional enrichment analysis revealed that immune function and the interferon signaling pathway were enriched...
Our bioinformatics analysis identified new genetic biomarkers of the pathogenesis of PM/DM. We demonstrated that immune cell infiltration plays a pivotal part in the occurrence of PM/DM....
This paper aims to investigate the clinical and laboratory test characteristics of patients with anti-MDA5 antibody-positive PM/DM by analyzing the clinical characteristics, laboratory test results, a...
To characterize morphological and molecular underpinnings of polymyositis with mitochondrial pathology (PM-Mito) in comparison with sporadic inclusion body myositis (IBM) and to define common and dist...
In this cross-sectional study, skeletal muscle biopsy samples and clinical and laboratory data from patients with PM-Mito and IBM were analyzed at Charité university hospital in Berlin, Germany. All a...
Twenty-five skeletal muscle biopsy samples of patients with PM-Mito and IBM were included in the study and compared with 5 biopsy samples from NDCs. PM-Mito and IBM qualitatively harbored a strikingly...
Our combined data suggest that specific IFN-mediated inflammation plays a key role in both IBM and PM-Mito. GBP6 was identified as a new molecule of type II IFN-induced inflammation distinguishing IBM...
Serum uric acid (UA), as an antioxidant, has been associated with hypertension in the general population. Hypertension is highly prevalent in patients with polymyositis and dermatomyositis (PM/DM). Ow...